The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation

Transplant International

Volumn 17, Issue 9, 2004, Pages 531-539

  Fabre, Margarete A ^a   Jones, Des C ^a   Bunce, Mike ^a   Morris, Peter J ^a   Friend, Peter J ^a   Welsh, Ken I ^b   Marshall, Sara E ^c  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Azathioprine; Genetic polymorphism; Pharmacogenetics; Renal transplantation; Thiopurine methyltransferase

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; METHYLTRANSFERASE; PREDNISOLONE; THIOPURINE S METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BONE MARROW APLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HOMOZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; VARIABLE NUMBER OF TANDEM REPEAT; WILD TYPE;

EID: 9944221077     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00483.x     Document Type: Article

References (41)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487.
2. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355:1358.
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase deficiency. Am J Hum Genet 1980; 32:651.
4. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39:19.
5. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4:1.
6. Carney DM, Zukoski CF, Ogden DA. Massive azathioprine overdose. Case report and review of the literature. Am J Med 1974; 56:133.
7. Hendrick D, Mirkin BL. Metabolic disposition and toxicity of 6-mercaptopurine after massive overdose (letter). Lancet 1984; 1:277.
8. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149.
9. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17.
10. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14:567.
11. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad SCi U S A 1997; 94:6444.
12. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994; 343:1188.
13. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716.
14. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001.
15. Sebbag L, Boucher P, Davelu P, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000; 69:1524.
16. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999; 38:640.
17. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705.
18. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105:696.
19. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125:879.
20. Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000; 68:210.
21. Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther 2001; 70:165.
22. Marinaki AM, Arenas M, Khan ZH, et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 2003; 13:97.
23. Van der Bij W, Torensma R, Van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25:179.
24. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39:225.
25. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F, et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999; 9:189.
26. Opelz G, Dohler B. Critical threshold of azathioprine dosage for maintenance immunosuppression in kidney graft recipients. Transplantation 2000; 69:818.
27. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85:323.
28. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85:1897.
29. Weyer N, Kroplin T, Fricke L, Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001; 57:129.
30. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47:131.
31. Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 2003; 38:972.
32. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608.
33. Coulthard SA, Rabello C, Robson J, et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol 2000; 110:599.
34. Bunce M, O'Neill C, Barnardo MCNM, et al. "Phototyping": comprehensive DNA typing for HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, and -DQB alleles by 144 PCR reactions utilising sequence specific primers (SSP). Tissue Antigens 1995; 46:355.
35. Schutz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, " two-color/shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design (In Process Citation). Clin Chem 2000; 46:1728.
36. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694.
37. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8:367.
38. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081.
39. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 1995; 92:949.
40. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60.
41. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12:177.